Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

1,274 total articles

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

LB Pharmaceuticals reported positive results from Phase 2 trials of LB-102 in schizophrenia, initiated pivotal Phase 3 and additional Phase 2 trials for bipolar depression and major depressive disorder, and announced a $100 million private placement. The company has a strong cash position of $295.2 million as of December 31, 2025, providing a runwa…

Alpine Income Property Trust Announces First Quarter 2026 Earnings Release and Conference Call Information

Alpine Income Property Trust Announces First Quarter 2026 Earnings Release and Conference Call Information

Alpine Income Property Trust, Inc., a publicly traded REIT focusing on single tenant net leased commercial properties and commercial loan investments, announced it will release its Q1 2026 financial results after market close on April 23, 2026, followed by a conference call on April 24, 2026. The company aims to provide updates on its portfolio and…

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights

Arcadia Biosciences announced its financial results for Q4 and full year 2025, reporting a 17% increase in Zola coconut water revenues and significant reductions in SG&A expenses and net cash used in operations. The company also disclosed the termination of a proposed business combination with Roosevelt Resources and the exercise of preferred inves…

Xanadu Quantum Technologies Limited Announces Closing of Business Combination with Crane Harbor Acquisition Corp. and Xanadu Quantum Technologies Inc.

Xanadu Quantum Technologies Limited Announces Closing of Business Combination with Crane Harbor Acquisition Corp. and Xanadu Quantum Technologies Inc.

Xanadu Quantum Technologies Limited has successfully closed its business combination with Crane Harbor Acquisition Corp., a publicly traded SPAC, along with a $275 million PIPE financing. The company will begin trading on Nasdaq and the Toronto Stock Exchange on March 27, 2026, under the ticker symbol XNDU. Xanadu positions itself as the first pure…

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly

Crinetics Pharmaceuticals has submitted a Marketing Authorization Application to Brazil's ANVISA for Palsonify (paltusotine), the first once-daily oral therapy approved in the US for acromegaly. The submission follows positive Phase 3 trial results demonstrating efficacy and tolerability and complements recent regulatory progress in Europe. This ma…

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Kyverna Therapeutics reported significant progress in its autoimmune CAR T therapy pipeline, particularly with miv-cel (KYV-101) showing positive clinical results in stiff person syndrome (SPS), generalized myasthenia gravis (gMG), and progressive multiple sclerosis. The company plans a Biologics License Application (BLA) submission for SPS in the …

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

Zenas BioPharma has commenced underwritten public offerings of convertible senior notes due 2032 and common stock. The company plans to use net proceeds to support the U.S. commercial launch of obexelimab, advance its clinical development pipeline including Phase 3 trials of orelabrutinib, and for general corporate purposes. The offerings are subje…

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics, a Nasdaq-listed clinical-stage biotech company, successfully closed its underwritten public offering, raising approximately $403 million. The offering included 5,750,000 shares sold at $70 each and full exercise of underwriters' options. Proceeds will support the company’s development of novel biologics targeting inflammatory a…

SIGA Declares Special Cash Dividend of $0.60 Per Share

SIGA Declares Special Cash Dividend of $0.60 Per Share

SIGA Technologies declared a special cash dividend of $0.60 per share payable on April 23, 2026. This dividend demonstrates SIGA's strong financial position and commitment to rewarding shareholders while continuing its work in biodefense, especially smallpox preparedness amid geopolitical uncertainties.

Alamos Gold Provides Notice of Completion of Annual Filings

Alamos Gold Provides Notice of Completion of Annual Filings

Alamos Gold Inc. has filed its annual information form and 2025 annual report including audited financial statements with both the U.S. SEC and Canadian securities authorities. These documents are accessible online and available to shareholders upon request. The company operates gold mines in Canada and Mexico and has several growth projects underw…

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) is in advanced-stage evaluation to acquire a niche contract research organization (CRO) with operations in over 20 countries, poised to add $20 million+ in annual revenue and support double-digit growth. This potential acquisition aligns with Tevogen's strategy to diversify and expand its healthcare services…

XA Investments Appoints Lauren Michalak as Managing Director and Head of Product Development & Strategy

XA Investments Appoints Lauren Michalak as Managing Director and Head of Product Development & Strategy

XA Investments LLC has appointed Lauren Michalak as managing director and head of product development and strategy. Michalak brings two decades of experience from Nuveen, focusing on product innovation, strategic initiatives, and capital raising. She will lead product efforts for XAI's closed-end funds and consulting clients, aiming to expand the f…

Amesite Executes Trading Partner Agreement Enabling Secure Connectivity with Leading Homecare Technology Platform

Amesite Executes Trading Partner Agreement Enabling Secure Connectivity with Leading Homecare Technology Platform

Amesite Inc. announced a Trading Partner Agreement with a leading homecare technology platform, enabling its AI-driven NurseMagic EMR to securely connect and streamline electronic visit verification (EVV) in compliance with HIPAA and CMS regulations. This integration enhances interoperability and compliance for non-acute care providers and marks a …

GlobalFoundries Files Patent Infringement Lawsuits Against Tower Semiconductor to Protect High-Performance American Chip Innovation

GlobalFoundries Files Patent Infringement Lawsuits Against Tower Semiconductor to Protect High-Performance American Chip Innovation

GlobalFoundries filed multiple lawsuits in U.S. courts against Tower Semiconductor, alleging infringement of 11 U.S. patents covering advanced semiconductor manufacturing processes. The legal actions aim to halt Tower's importation and sales of products using these patented technologies and to seek compensation for lost profits. GF emphasizes its s…